More than 90% of patients received HF neprilysin, including angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker or angiotensin receptor/neprilysin inhibitor therapy [ACEi/ARB/ARNi] and beta-blockers [Table 1]. The gene discussed is ACE; the disease is hydrops fetalis.